Brief: OSE, Servier Complete Patient Enrollment In Sjogren's Syndrome Study

Ose Immunotherapeutics SA

03/11/2022 06:35

Nov 3 (Reuters) - OSE IMMUNOTHERAPEUTICS SA  OSE.PA :
    * SERVIER AND OSE IMMUNOTHERAPEUTICS ANNOUNCE COMPLETION OF
PATIENT ENROLLMENT IN THE PHASE 2A CLINICAL TRIAL OF
OSE-127/S95011 IN PRIMARY SJÖGREN'S SYNDROME
    * STUDY INCLUDES 48 PATIENTS ACROSS A SCORE OF CENTERS
LOCATED IN
UNITED STATES, AUSTRALIA AND EUROPE
    * RESULTS ARE EXPECTED IN 2023

Source text for Eikon:  ID:nBw4TN0nja 
Further company coverage:  OSE.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))